EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, is announced as the winner of the Biotech & Pharmaceuticals category, at the European Innovation Council Investor Day on Health 2021.

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, announced today that it is the recipient of a €2.7 million convertible loan agreement from the European Innovation Council (EIC) Fund.

First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases Commences at the Medicines Evaluation Unit in Manchester, UK.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board of Directors.

EpiEndo Pharmaceuticals is pleased to announce that their consortium project EPIcoliX has been officially recognized as a Eurostar labelled project.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Professor Dr Michael Parnham, PhD, CBiol, MRSB, FBPhS as Chief Scientific Officer (CSO) and Dr Ginny Norris, MRCP, FFPM, DCPSA, in the role of Chief Medical Officer (CMO).

The Board of EpiEndo Pharmaceuticals is pleased to announce the appointment of Maria Bech, MSc as Chief Executive Officer (CEO) of the Company, effective immediately.

EpiEndo Pharmaceuticals announced today that the Company has received approval of its Clinical Trial Application (CTA) from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to commence phase 1 clinical trials of EP395, the Company's lead compound.

EpiEndo Pharmaceuticals is pleased to share important findings in a poster at the ERS (European Respiratory Society) International Congress this year.